Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

NCT05190523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: ASC42 5 mg
DRUG: ASC42 10 mg
DRUG: ASC42 15 mg
DRUG: Placebo

Sponsor

Gannex Pharma Co., Ltd.